Operating profit EBITDA: Verrica Pharmaceuticals (VRCA)

Public company logo of verrica.com (VRCA)

Verrica Pharmaceuticals (VRCA) attracts experts with ambitious dermatology projects, supported by a rigorous KPI system and generous bonuses. The EBITDA figure demonstrates business resilience, where 0.00 represents the current level of the metric. The company is optimizing drug rollouts by leveraging external manufacturers, international logistics, and automated clinical trial data analysis.

Profit before payment of interest, taxes and amortization: verrica.com (VRCA) for 11/23/2025 - 11/17/2026

Verrica Pharmaceuticals Inc. (VRCA) - metric breakdowns and financial figures

- stock value and consensus price forecast:
- company stock exchange capitalization indicators:
Analysis of all company metrics:Verrica Pharmaceuticals Inc.
Manufactured products of verrica.com

This indicator measures net cash flow from operating activities before accounting for depreciation and borrowing costs, allowing for an assessment of real resource generation efficiency. The EBITDA trend for Verrica Pharmaceuticals (VRCA) demonstrates how the commercialization of the unique drug YCANTH is transforming market leadership in the therapy of viral skin lesions into a sustainable financial foundation for the business.